Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of CAD106 in mild Alzheimer's disease
2009-012395-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amilomotide in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Jun 2009; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-012395-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012395-27.